Date:7/29/2009

---- Net loss (22,878,464) (13,568,418) (31,241,899) (23,193,323) Deemed distribution to preferred stockholders (26,375,000) - (26,375,000) - ----------- ----------- ----------- ----------- Loss attributable to common stockholders $(49,253,464) $(13,568,418) $(57,616,899) $(23,193,323) ============ ============ ============ ============ Basic and diluted loss attributable to common stockholders per common share $(1.43) $(0.39) $(1.67) $(0.67) Shares used in computing basic and diluted loss attributable to common stockholders per common share 34,412,870 34,377,367 34,411,327 34,371,132

'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences